Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared on LinkedIn:
“AI in Pharma R/D: time to move from better models – better medicines
- Optimize what matters: improving Phase II success has far greater potential impact than simply accelerating hit discovery
- Ligand ≠ drug: AI can generate binders rapidly – but efficacy requires the right biology, exposure, safety and patient
- Better data ≠ more data: biological data are highly contextual; what matters is predictive validity for human outcomes
- Benchmark ≠ impact: model accuracy matters only if it improves a real R/D decision – advance, redesign or stop
- Next frontier: start with the clinical question – generate fit-for-purpose human biology – integrate clinical feedback – continuously improve the model
Perhaps the end of the beginning: less ‘technology push,’ more ‘science pull.’
